^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    GENE:

    HER-2 (Human epidermal growth factor receptor 2)

    i
    Other names: ERBB2, CD340, HER-2, HER2, NEU, NGL, V-erb-b2 avian erythroblastic leukemia viral oncogene homolog 2
    1d
    Omission of Axillary Lymph Node Dissection in Early-Stage Breast Cancer With Limited Sentinel Lymph Node Metastasis: A Propensity Score-Matched Analysis. (PubMed, Clin Breast Cancer)
    In cN0 breast cancer patients with 1 to 3 positive SLNs, omitting ALND did not compromise OS or RFS after mastectomy or breast-conserving surgery. These results support broader application of de-escalated axillary surgery while prospective validation for higher nodal burden remains necessary.
    Journal
    |
    HER-2 (Human epidermal growth factor receptor 2) • PGR (Progesterone receptor)
    1d
    HER2-dependent paraptosis and ferroptosis induction by cannabidiol in breast cancer cells. (PubMed, Biochim Biophys Acta Mol Basis Dis)
    These findings support a model in which CBD downregulates HER2 and, in a HER2-dependent context, promotes paraptosis and ferroptosis. In addition, docking and molecular dynamics analyses suggested a potential interaction between CBD and HER2, providing mechanistic insights into possible molecular recognition relevant to HER2-positive breast cancer.
    Journal
    |
    HER-2 (Human epidermal growth factor receptor 2) • GPX4 (Glutathione Peroxidase 4) • SLC7A11 (Solute Carrier Family 7 Member 11) • ATF4 (Activating Transcription Factor 4)
    |
    HER-2 positive • HER-2 overexpression • HER-2 negative • HER-2 positive + HER-2 overexpression
    1d
    Association of clinicopathological characteristics and baseline peripheral blood lymphocyte subsets with efficacy of first-line immunotherapy in advanced gastric cancer. (PubMed, Discov Oncol)
    Clinicopathological characteristics and baseline peripheral lymphocyte subsets were significantly associated with efficacy of first-line chemotherapy combined with ICIs in pMMR HER2-negative advanced G/GEJC, highlighting the potential utility of integrating these accessible parameters for efficacy prediction.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1)
    |
    HER-2 negative
    1d
    The safety of trastuzumab deruxtecan (T-DXd) in breast cancer brain metastases with a focus on interstitial lung disease/pneumonitis: A systematic review and meta-analysis. (PubMed, Cancer)
    In patients with BCBM, T-DXd-associated ILD/pneumonitis occurred in 10% of patient and frequently necessitated treatment modification. Although no fatal ILD was observed, the high discontinuation rate underscored the imperative for vigilant monitoring and protocol-guided management to mitigate pulmonary toxicity while preserving intracranial efficacy.
    Clinical • Retrospective data • Review • Journal
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive
    |
    Enhertu (fam-trastuzumab deruxtecan-nxki)
    1d
    Emulation of the PALOMA-2 Trial (clinicaltrials.gov)
    P=N/A, N=6097, Active, not recruiting, Brigham and Women's Hospital | Trial completion date: Oct 2025 --> Mar 2026 | Trial primary completion date: Oct 2025 --> Mar 2026
    Trial completion date • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor)
    |
    ER positive • HER-2 negative • HER-2 negative + ER positive
    |
    Ibrance (palbociclib) • letrozole
    1d
    Paclitaxel and Ramucirumab +/- Zanidatamab in HER2 Postive Advanced Gastroesophageal Adenocarcinoma (clinicaltrials.gov)
    P2, N=168, Recruiting, Canadian Cancer Trials Group | Trial completion date: Jun 2026 --> Dec 2026 | Trial primary completion date: Dec 2025 --> Jun 2026
    Trial completion date • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive
    |
    paclitaxel • Cyramza (ramucirumab) • Ziihera (zanidatamab-hrii)
    1d
    A Study of Tucatinib and Trastuzumab in People With Rectal Cancer (clinicaltrials.gov)
    P2, N=37, Recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Dec 2025 --> Dec 2026 | Trial primary completion date: Dec 2025 --> Dec 2026
    Trial completion date • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • KRAS (KRAS proto-oncogene GTPase)
    |
    HER-2 positive • HER-2 overexpression • HER-2 amplification • RAS wild-type • HER-2 positive + HER-2 overexpression • HER-2 positive + RAS wild-type
    |
    Herceptin (trastuzumab) • Tukysa (tucatinib)
    1d
    CFI-400945 in Patients With Advanced/Metastatic Breast Cancer (clinicaltrials.gov)
    P2, N=51, Active, not recruiting, Canadian Cancer Trials Group | Trial completion date: Dec 2025 --> Dec 2026 | Trial primary completion date: Dec 2025 --> Jun 2026
    Trial completion date • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • PGR (Progesterone receptor) • PTEN (Phosphatase and tensin homolog)
    |
    PTEN mutation
    |
    ocifisertib (CFI-400945)
    1d
    X-ray Psoralen Activated Cancer Therapy in Head and Neck, Breast, Sarcoma and Melanoma (clinicaltrials.gov)
    P1, N=52, Recruiting, Immunolight, LLC | N=20 --> 52
    Enrollment change
    |
    HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • ER (Estrogen receptor) • PGR (Progesterone receptor) • BRCA1 (Breast cancer 1, early onset) • BRCA (Breast cancer early onset)
    |
    HER-2 negative • ER negative
    |
    methoxsalen (X-PACT)
    1d
    Clinical Study of SHR-A1811 Combined With Pertuzumab as Second-Line Therapy in Patients With HER2-Altered Advanced NSCLC (clinicaltrials.gov)
    P=N/A, N=60, Not yet recruiting, The First Affiliated Hospital of Guangzhou Medical University
    New trial
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 overexpression • HER-2 amplification • HER-2 mutation
    |
    Perjeta (pertuzumab) • trastuzumab rezetecan (SHR-A1811)